OIG. 1988. Kidney acquisition costs: A management advisory report. Washington, D.C., November.
OIG. 1990. The effect of the interim payment rate for the drug Epogen on Medicare expenditures and dialysis facility operations. Draft report. Washington, D.C., May.
OTA (Office of Technology Assessment). 1990. Recombinant erythropoietin: Payment options for Medicare. OTA-H-451. Washington, D.C.: Government Printing Office .
REN Corporation-USA. 1989. Prospectus, November 28. Nashville, Tenn.
Rettig RA. 1980. The politics of health cost containment: End-stage renal disease. Bull NY Acad Med 56:115–138.
SSA (Social Security Administration, Bureau of Health Insurance). 1974. Alternative reimbursement method of monthly payments to physicians for services rendered to patients on maintenance dialysis. Intermediary Letter No. 74-29(A)(3). June.
Trude S, Carter GM. 1989. A description of expensive and long-staying patients. N-2998-HCFA. The RAND Corporation. Santa Monica, Calif.
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Part IV: Reimbursement and Quality, Medicare ESRD Payment Policy ."
Kidney Failure and the Federal Government . Washington, DC: The National Academies Press,
Please select a format: